The 10b5-1 plan removes timing suspicion, this is a scheduled monetization of option exercises, not a conviction sell signal. The filing is routine for an insider with large equity grants. Monitor for any filings that accelerate or expand the plan, but no trading action warranted on this notice alone.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $156.58entry
- T+1 · 5mo ago +0.76%α +2.01% · $157.77
- T+5 · 5mo ago +8.26%α +10.49% · $169.51
- T+20 · 4mo ago +18.13%α +17.93% · $184.97
- T+60 · 2mo ago +29.87%α +28.87% · $203.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Margaret A. Horn, an officer at Revolution Medicines, filed a Form 144 to sell 90,000 common shares (~$13.85M at filing price). The sale is pursuant to a Rule 10b5-1 plan, with shares acquired upon exercise of stock options. The advance notice signals planned monetization of equity compensation, not an opportunistic sale.
Key Facts
- Insider: Margaret A. Horn (Officer)
- Shares proposed for sale: 90,000 common shares
- Estimated value: approx. $13.85 million ($153.87 per share)
- Sale plan: Rule 10b5-1 trading arrangement adopted March 12, 2026
- Prior sale on June 11, 2026: 10,000 shares for ~$1.48M
- Prior sale on March 17, 2026: 4,583 shares for ~$455.9K
- Shares are from option exercises, not open-market holdings
Financial Impact
Proposed sale of $13.85M (0.04% of $32.7B market cap). Minimal dilution/supply impact.
Risk Factors
- If subsequent open-market sales accelerate beyond the plan, it could signal insider caution
- Insider has already sold ~$1.9M in June 2026 under the plan, consistent with routine diversification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006148 |
| Document: 0001950047-26-006148-index.html | 0001950047-26-006148 |
| Document: 0001950047-26-006148.txt | 0001950047-26-006148 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers